Lincoln Pharmaceuticals: Sr. General Manager - QA (Head QA) Manoj Rai Resigns
Mr. Manoj Rai, Sr. General Manager - QA (Head QA) at Lincoln Pharmaceuticals Limited, has resigned due to personal reasons. His resignation is effective September 24, 2026. Mr. Rai is pursuing new professional opportunities and will ensure a smooth handover of responsibilities.
While a senior management change can be significant, the announcement does not provide details on the impact of Mr. Rai's departure on the company's operations or financial performance. The resignation is due to personal reasons, and a smooth transition is expected.
The resignation of a senior management personnel is a routine event and does not inherently carry a positive or negative financial implication for the company without further context. The reasons cited are personal.
Lincoln Pharmaceuticals Limited has announced the resignation of Mr. Manoj Rai, Sr. General Manager - QA (Head QA), a key member of its senior management personnel. The resignation is effective from September 24, 2026, after the close of business hours, and has been submitted due to personal reasons.
Mr. Rai's resignation was formally communicated to the National Stock Exchange of India Limited (NSE) and BSE Limited on September 24, 2026. The company has provided the necessary disclosures as per SEBI's Master Circular and has enclosed a copy of Mr. Rai's resignation letter, which outlines his reasons for leaving and his gratitude to the organization.
In his resignation letter, Mr. Rai expressed his decision to pursue a new professional opportunity. He thanked the management, leadership team, and colleagues for their support during his tenure. He also indicated his willingness to serve the prescribed notice period and ensure a smooth transition of responsibilities, while also requesting to be relieved earlier by adjusting his leave balance, subject to organizational approval.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.